Online first
Review paper
Published online: 2024-08-06
mRNA vaccines in the treatment of cancer
1
, 1, 1
, 1, 1
DOI: 10.5603/ocp.101582
Abstract
Even though studies on mRNA vaccines have been performed since the 1990s, the first clinical trials of their usage were conducted in the late 2010s. The COVID-19 pandemic created an urgent need for effective vaccine development and prompted large-scale research on mRNA vaccines. Large studies enabled the improvement of mRNA vaccine structure and optimization of their delivery platforms, which contributed to a rise in both their efficacy and safety. Currently, mRNA vaccines are used not only in infectious diseases but also are being tested in research on cancer patients. Using next-generation sequencing (NGS) in mRNA vaccine manufacture seems to be beneficial because it enables preparation of personalized vaccines encoding tumor-specific antigens (TSAs). Tumor-specific antigens-based vaccines are associated with a stronger immune response and lower toxicity compared to non-personalized vaccines. Currently, clinical trials on mRNA vaccines are performed in patients with various types of cancer: pancreatic, non-small-cell lung, prostate cancers as well as melanomas. Due to the benefits of mRNA cancer vaccine administration in monotherapy, their combination with chemotherapy, radiotherapy, or immune checkpoint inhibitors (ICIs) have been suggested. In this review, we highlight the latest findings on mRNA vaccine development, including the advantages of using NGS during their production. We also summarize the current Food and Drug Administration (FDA) indications, results of completed clinical trials, and future possibilities of using mRNA vaccines in treatment of cancer patients.
Keywords: mRNA vaccinesneoantigensimmunotherapycancer
References
- Huang T, Peng L, Han Y, et al. Lipid nanoparticle-based mRNA vaccines in cancers: Current advances and future prospects. Front Immunol. 2022; 13: 922301.
- Gu J, Xu Z, Liu Q, et al. Building a Better Silver Bullet: Current Status and Perspectives of Non-Viral Vectors for mRNA Vaccines. Adv Healthc Mater. 2024; 13(3): e2302409.
- Ramachandran S, Satapathy SR, Dutta T. Delivery Strategies for mRNA Vaccines. Pharmaceut Med. 2022; 36(1): 11–20.
- Rosa SS, Prazeres DMF, Azevedo AM, et al. mRNA vaccines manufacturing: Challenges and bottlenecks. Vaccine. 2021; 39(16): 2190–2200.
- Xu S, Yang K, Li R, et al. mRNA Vaccine Era-Mechanisms, Drug Platform and Clinical Prospection. Int J Mol Sci. 2020; 21(18).
- Yao R, Xie C, Xia X. Recent progress in mRNA cancer vaccines. Hum Vaccin Immunother. 2024; 20(1): 2307187.
- Wang B, Pei J, Xu S, et al. Recent advances in mRNA cancer vaccines: meeting challenges and embracing opportunities. Front Immunol. 2023; 14: 1246682.
- Türeci Ö, Vormehr M, Diken M, et al. Targeting the Heterogeneity of Cancer with Individualized Neoepitope Vaccines. Clin Cancer Res. 2016; 22(8): 1885–1896.
- Hollingsworth RE, Jansen K. Turning the corner on therapeutic cancer vaccines. NPJ Vaccines. 2019; 4: 7.
- Zhang X, Sharma PK, Peter Goedegebuure S, et al. Personalized cancer vaccines: Targeting the cancer mutanome. Vaccine. 2017; 35(7): 1094–1100.
- Deng Z, Tian Y, Song J, et al. mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy. Front Immunol. 2022; 13: 887125.
- Han R, Wang Y, Lu L. Sensitizing the Efficiency of ICIs by Neoantigen mRNA Vaccines for HCC Treatment. Pharmaceutics. 2023; 16(1).
- Fotin-Mleczek M, Zanzinger K, Heidenreich R, et al. Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect. J Gene Med. 2012; 14(6): 428–439.
- Fotin-Mleczek M, Zanzinger K, Heidenreich R, et al. mRNA-based vaccines synergize with radiation therapy to eradicate established tumors. Radiat Oncol. 2014; 9: 180.
- Lorentzen CL, Haanen JB, Met Ö, et al. Clinical advances and ongoing trials on mRNA vaccines for cancer treatment. Lancet Oncol. 2022; 23(10): e450–e458.
- Parkhurst MR, Yang JC, Langan RC, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther. 2011; 19(3): 620–626.
- Subramanian R, Meganathan P, Selvarajan R. mRNA Vaccine - Game Changer against Infectious Disease. Int J Health Sci Res. 2022; 12(7): 250–270.
- Liu J, Fu M, Wang M, et al. Cancer vaccines as promising immuno-therapeutics: platforms and current progress. J Hematol Oncol. 2022; 15(1): 28.
- Warminski M, Mamot A, Depaix A, et al. Chemical Modifications of mRNA Ends for Therapeutic Applications. Acc Chem Res. 2023; 56(20): 2814–2826.
- Chen J, Ye Z, Huang C, et al. Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8 T cell response. Proc Natl Acad Sci U S A. 2022; 119(34): e2207841119.
- Schlake T, Thess A, Fotin-Mleczek M, et al. Developing mRNA-vaccine technologies. RNA Biol. 2012; 9(11): 1319–1330.
- Beck JD, Reidenbach D, Salomon N, et al. mRNA therapeutics in cancer immunotherapy. Mol Cancer. 2021; 20(1): 69.
- Wang Y, Zhang Z, Luo J, et al. mRNA vaccine: a potential therapeutic strategy. Mol Cancer. 2021; 20(1): 33.
- Kwon S, Kwon M, Im S, et al. mRNA vaccines: the most recent clinical applications of synthetic mRNA. Arch Pharm Res. 2022; 45(4): 245–262.
- Linares-Fernández S, Lacroix C, Exposito JY, et al. Tailoring mRNA Vaccine to Balance Innate/Adaptive Immune Response. Trends Mol Med. 2020; 26(3): 311–323.
- Gómez-Aguado I, Rodríguez-Castejón J, Vicente-Pascual M, et al. Nanomedicines to Deliver mRNA: State of the Art and Future Perspectives. Nanomaterials (Basel). 2020; 10(2).
- McCaffrey A. RNA Epitranscriptome: Role of the 5' Cap. Genetic Engineering & Biotechnology News. 2019; 39(5): 59, 61.
- Wojtczak BA, Sikorski PJ, Fac-Dabrowska K, et al. 5'-Phosphorothiolate Dinucleotide Cap Analogues: Reagents for Messenger RNA Modification and Potent Small-Molecular Inhibitors of Decapping Enzymes. J Am Chem Soc. 2018; 140(18): 5987–5999.
- Inagaki M, Abe N, Li Z, et al. Cap analogs with a hydrophobic photocleavable tag enable facile purification of fully capped mRNA with various cap structures. Nat Commun. 2023; 14(1): 2657.
- Litvinova VR, Rudometov AP, Karpenko LI, et al. mRNA Vaccine Platform: mRNA Production and Delivery. Russ J Bioorg Chem. 2023; 49(2): 220–235.
- Karikó K, Muramatsu H, Ludwig J, et al. Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Res. 2011; 39(21): e142.
- Ho W, Gao M, Li F, et al. Next-Generation Vaccines: Nanoparticle-Mediated DNA and mRNA Delivery. Adv Healthc Mater. 2021; 10(8): e2001812.
- Jenks S. Gene therapy death--"everyone has to share in the guilt". J Natl Cancer Inst. 2000; 92(2): 98–100.
- Dailey GP, Crosby EJ, Hartman ZC. Cancer vaccine strategies using self-replicating RNA viral platforms. Cancer Gene Ther. 2023; 30(6): 794–802.
- Pardi N, Hogan MJ, Porter FW, et al. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 2018; 17(4): 261–279.
- Savar NS, Vallet T, Arashkia A, et al. Packaging, Purification, and Titration of Replication-Deficient Semliki Forest Virus-Derived Particles as a Self-Amplifying mRNA Vaccine Vector. Iran Biomed J. 2022; 26(4): 269–278.
- Morse MA, Crosby EJ, Force J, et al. Clinical trials of self-replicating RNA-based cancer vaccines. Cancer Gene Ther. 2023; 30(6): 803–811.
- Barbier AJ, Jiang AY, Zhang P, et al. The clinical progress of mRNA vaccines and immunotherapies. Nat Biotechnol. 2022; 40(6): 840–854.
- Samaridou E, Heyes J, Lutwyche P. Lipid nanoparticles for nucleic acid delivery: Current perspectives. Adv Drug Deliv Rev. 2020; 154-155: 37–63.
- Vishweshwaraiah YL, Dokholyan NV. mRNA vaccines for cancer immunotherapy. Front Immunol. 2022; 13: 1029069.
- Hou X, Zaks T, Langer R, et al. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021; 6(12): 1078–1094.
- Shi Da, Beasock D, Fessler A, et al. To PEGylate or not to PEGylate: Immunological properties of nanomedicine's most popular component, polyethylene glycol and its alternatives. Adv Drug Deliv Rev. 2022; 180: 114079.
- Qin Z, Bouteau A, Herbst C, et al. Pre-exposure to mRNA-LNP inhibits adaptive immune responses and alters innate immune fitness in an inheritable fashion. PLoS Pathog. 2022; 18(9): e1010830.
- Houseley J, Tollervey D. The many pathways of RNA degradation. Cell. 2009; 136(4): 763–776.
- Diken M, Kreiter S, Selmi A, et al. Antitumor vaccination with synthetic mRNA: strategies for in vitro and in vivo preclinical studies. Methods Mol Biol. 2013; 969: 235–246.
- Overwijk WW. Cancer vaccines in the era of checkpoint blockade: the magic is in the adjuvant. Curr Opin Immunol. 2017; 47: 103–109.
- Vormehr M, Türeci Ö, Sahin U. Harnessing Tumor Mutations for Truly Individualized Cancer Vaccines. Annu Rev Med. 2019; 70: 395–407.
- Lang F, Schrörs B, Löwer M, et al. Identification of neoantigens for individualized therapeutic cancer vaccines. Nat Rev Drug Discov. 2022; 21(4): 261–282.
- Sahin U, Türeci Ö. Personalized vaccines for cancer immunotherapy. Science. 2018; 359(6382): 1355–1360.
- Lebofsky R, Decraene C, Bernard V, et al. Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types. Mol Oncol. 2015; 9(4): 783–790.
- Rojas LA, Sethna Z, Soares KC, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023; 618(7963): 144–150.
- Bechter O, Utikal J, Baurain JF, et al. 391 A first-in-human study of intratumoral SAR441000, an mRNA mixture encoding IL-12sc, interferon alpha2b, GM-CSF and IL-15sushi as monotherapy and in combination with cemiplimab in advanced solid tumors. Regular and young investigator award abstracts. 2020.
- Hewitt SL, Bai A, Bailey D, et al. Durable anticancer immunity from intratumoral administration of IL-23, IL-36γ, and OX40L mRNAs. Sci Transl Med. 2019; 11(477).
- Hotz C, Wagenaar TR, Gieseke F, et al. Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models. Sci Transl Med. 2021; 13(610): eabc7804.
- Jimeno A, Gupta S, Sullivan R, et al. Abstract CT032: A phase 1/2, open-label, multicenter, dose escalation and efficacy study of mRNA-2416, a lipid nanoparticle encapsulated mRNA encoding human OX40L, for intratumoral injection alone or in combination with durvalumab for patients with advanced malignancies. Cancer Research. 2020; 80(16_Supplement): CT032–CT032.
- Klein AP. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol. 2021; 18(7): 493–502.
- Zhao Z, Liu W. Pancreatic Cancer: A Review of Risk Factors, Diagnosis, and Treatment. Technol Cancer Res Treat. 2020; 19: 1533033820962117.
- Zhu H, Wei M, Xu J, et al. PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications. Mol Cancer. 2020; 19(1): 49.
- Casolino R, Biankin AV. Treatment of pancreatic cancer in 2022. Camb Prism Precis Med. 2023; 1: e14.
- Sethna Z, Guasp P, Reiche, C, et al. CT025 -Personalized RNA Neoantigen Vaccines Induce Long-Lived CD8+ T Effector Cells in Pancreatic Cancer. Presented at: 2024 AACR Annual Meeting; April 7, 2024; San Diego, CA.
- Lopez J, Camidge R, Iafolla M, et al. Abstract CT301: A phase Ib study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in combination with atezolizumab in patients with locally advanced or metastatic solid tumors. Cancer Research. 2020; 80(16_Supplement): CT301–CT301.
- A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected Pancreatic Ductal Adenocarcinoma. https://clinicaltrials.gov/study/NCT05968326 (03.07.2024).
- https://clinicaltrials.gov/search?cond=RO7198457 (03.07.2024).
- Jenkins RW, Fisher DE. Treatment of Advanced Melanoma in 2020 and Beyond. J Invest Dermatol. 2021; 141(1): 23–31.
- Cassarino DS, Miller WJ, Auerbach A, et al. The effects of gp100 and tyrosinase peptide vaccinations on nevi in melanoma patients. J Cutan Pathol. 2006; 33(5): 335–342.
- Villani A, Potestio L, Fabbrocini G, et al. The Treatment of Advanced Melanoma: Therapeutic Update. Int J Mol Sci. 2022; 23(12).
- Sahin U, Oehm P, Derhovanessian E, et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature. 2020; 585(7823): 107–112.
- Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV Melanoma. https://clinicaltrials.gov/study/NCT04526899 (03.07.2024).
- Burris H, Patel M, Cho D, et al. A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with pembrolizumab in patients with unresectable solid tumors. J Clin Oncol. 2019; 37(15_suppl): 2523–2523.
- Khattak A, Carlino M, Meniawy T, et al. Abstract CT001: A personalized cancer vaccine, mRNA-4157, combined with pembrolizumab versus pembrolizumab in patients with resected high-risk melanoma: Efficacy and safety results from the randomized, open-label Phase 2 mRNA-4157-P201/Keynote-942 trial. Cancer Research. 2023; 83(8_Supplement): CT001–CT001.
- Khattak A, Weber J, Meniawy T, et al. Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial. J Clin Oncol. 2023; 41(17_suppl): LBA9503–LBA9503.
- https://clinicaltrials.gov/search?cond=mRNA-4157%20 (03.07.2024).
- Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024; 74(1): 12–49.
- Planchard D, Popat S, Kerr K, et al. ESMO Guidelines Committee. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018; 29(Suppl 4): iv192–iv237.
- Zhou S, Yang H. Immunotherapy resistance in non-small-cell lung cancer: From mechanism to clinical strategies. Front Immunol. 2023; 14: 1129465.
- Sebastian M, Schröder A, Scheel B, et al. A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer. Cancer Immunol Immunother. 2019; 68(5): 799–812.
- Chen DT, Sabari J, Thompson J, et al. Abstract CT052: A phase IB study of mRNA-based active cancer vaccine, BI1361849, combined with durvalumab and tremelimumab immunotherapy in patients with non-small cell lung cancer (NSCLC). Cancer Research. 2024; 84(7_Supplement): CT052–CT052.
- Wang G, Zhao Di, Spring DJ, et al. Genetics and biology of prostate cancer. Genes Dev. 2018; 32(17-18): 1105–1140.
- Sekhoacha M, Riet K, Motloung P, et al. Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches. Molecules. 2022; 27(17).
- Stenzl A, Feyerabend S, Syndikus I, et al. Results of the randomized, placebo-controlled phase I/IIB trial of CV9104, an mRNA based cancer immunotherapy, in patients with metastatic castration-resistant prostate cancer (mCRPC). Ann Oncol. 2017; 28: v408–v409.